Subtype
Malignant Peritoneal Neoplasm
CI-CAN-00001164Explore in graph →
124 active trials5 approved drugs
- NCIt
- C3538
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001164Explore in graph →
Clinical trials
502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (75)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05581719 | A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | terminated | Phase 1 / Phase 2 | 14 | Enlivex Therapeutics RDO Ltd.INDUSTRY | 2 | Apr 17, 2024 | clinicaltrials |
| NCT03732950 | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | active not recruiting | Phase 2 | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03921658 | The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer | completed | — | 255 | University of MinnesotaOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT02996825 | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | completed | Phase 1 | 44 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01001910 | Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 22 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02728830 | A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers | completed | Early Phase 1 | 39 | AA SecordOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT02901899 | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 45 | Northwestern UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 16 | THERAPIM PTY LTDINDUSTRY | 1 | Feb 14, 2024 | clinicaltrials |
| NCT05083338 | Psychological, Psychophysical and Epigenetic Determinants of Chronic Pain After Cytoreductive - Hyperthermic Intraoperative Chemotherapy | completed | — | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | completed | Phase 1 / Phase 2 | 140 | Syndax PharmaceuticalsINDUSTRY | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT06161272 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | unknown | Phase 2 | 80 | Guangxi Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | terminated | N/A | 64 | University of WashingtonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03412630 | Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab | terminated | N/A | 1 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05960630 | MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer(MIRRORS-RCTP) | unknown | N/A | 20 | Royal Surrey County Hospital NHS Foundation TrustOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT01099644 | Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum | terminated | Phase 1 | 54 | Y-mAbs TherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT00112957 | Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 23 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00803569 | Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | completed | Phase 1 | 13 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01506856 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial(iPocc) | completed | Phase 2 / Phase 3 | 655 | Gynecologic Oncology Trial & Investigation ConsortiumNETWORK | 6 | Sep 15, 2023 | clinicaltrials |
| NCT00993655 | Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer | completed | Phase 2 | 275 | Canadian Cancer Trials GroupNETWORK | 4 | Aug 28, 2023 | clinicaltrials |
| NCT03363867 | BEACON - ABC in Recurrent Platinum Resistant HGSOC(BEACON) | unknown | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04201561 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy(SELENIUM) | unknown | Phase 3 | 68 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04678102 | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)(CREATIVE) | unknown | Phase 1 | 36 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05912972 | Development and Management of Registry in Patients With Gynecologic Cancer in Korea | recruiting | — | 13,500 | Asan Medical CenterOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT01891344 | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)(ARIEL2) | completed | Phase 2 | 491 | pharmaand GmbHINDUSTRY | 6 | Jun 12, 2023 | clinicaltrials |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | terminated | Phase 2 | 1 | pharmaand GmbHINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT01482715 | A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | completed | Phase 1 / Phase 2 | 136 | pharmaand GmbHINDUSTRY | 5 | Jun 9, 2023 | clinicaltrials |
| NCT01968213 | Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)(ARIEL3) | completed | Phase 3 | 564 | pharmaand GmbHINDUSTRY | 11 | Jun 9, 2023 | clinicaltrials |
| NCT02855944 | ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients | completed | Phase 3 | 349 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | completed | Phase 2 | 98 | Seagen Inc.INDUSTRY | 6 | May 6, 2023 | clinicaltrials |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT01974765 | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | completed | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT00538031 | Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | City of Hope Medical CenterOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05792254 | Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer | unknown | N/A | 30 | Ruijin HospitalOTHER | 0 | Mar 31, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02166905 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 1 / Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02973750 | Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer | completed | — | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04753216 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Northwestern UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT02489058 | A Study of Long-Term Responders on Olaparib(OLALA) | completed | — | 118 | University Health Network, TorontoOTHER | 5 | Jan 10, 2023 | clinicaltrials |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer(TOPACIO) | completed | Phase 1 / Phase 2 | 122 | Tesaro, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT03540017 | HIPEC After Initial CRS in Patients Who Have Received NACT | unknown | Phase 1 | 15 | Northwell HealthOTHER | 1 | Nov 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2024source: clinicaltrials